Related Experiment Video

Updated: Mar 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

CYP17 inhibitors in prostate cancer: latest evidence and clinical potential

Anitha B Alex1, Sumanta K Pal2, Neeraj Agarwal3

  • 1Division of Medical Oncology, Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.

Therapeutic Advances in Medical Oncology
|August 3, 2016
PubMed

Insights

Androgen deprivation therapy is standard for prostate cancer, but resistance develops. Newer inhibitors targeting CYP17 enzymes offer promising new treatments for metastatic castration-resistant prostate cancer by blocking androgen synthesis.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Androgen signaling drives prostate cancer proliferation and metastasis.
  • Androgen deprivation therapy (ADT) is a primary treatment, but resistance leads to metastatic castration-resistant prostate cancer (mCRPC).
  • Intratumoral androgen synthesis and androgen receptor (AR) signaling persist in mCRPC.

Purpose of the Study:

  • To review the molecular mechanisms, efficacy, and clinical potential of CYP17 inhibitors in prostate cancer.
  • To discuss newer CYP17 inhibitors beyond abiraterone acetate.
  • To highlight advancements in targeting extragonadal androgen synthesis for mCRPC treatment.

Main Methods:

  • Review of existing literature on CYP17 inhibitors.
  • Analysis of molecular mechanisms of action for various inhibitors.
  • Evaluation of clinical trial data and evidence for efficacy and safety.

Main Results:

  • Abiraterone acetate, a CYP17 inhibitor, is approved for mCRPC.
  • Newer CYP17 inhibitors (VT-464, orteronel, galeterone) show improved selectivity or dual AR signaling inhibition.
  • These agents target extragonadal androgen synthesis, a key driver in treatment-resistant prostate cancer.

Conclusions:

  • CYP17 inhibitors represent a significant therapeutic strategy for mCRPC.
  • Ongoing development of selective CYP17 inhibitors holds promise for improved patient outcomes.
  • Targeting androgen synthesis pathways remains crucial for managing advanced prostate cancer.
Keywords:
VT-464abirateroneandrogen biosynthesisandrogen receptorscastration-resistant prostate cancercytochrome P450 17α−hydroxy/17,20-lyase inhibitorsgaleteroneorteronel

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.0K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
585
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
689